Frazier Life Sciences logo

Frazier Life Sciences

Crunchbase
Pitchbook

Deals on record

6

Common Fundraising Type

Series B

Alesta Therapeutics logo
Alesta Therapeutics

Biotechnology

Frazier Life Sciences logo
Thuja Capital logo
SSI Strategy logo
RTW Investments logo
RV Invest logo
Novartis logo
Droia Ventures logo

Alesta Therapeutics is a biotechnology company developing oral small molecule therapies for rare diseases.

Series A
$67.4M
01/08/2025
Article
Maze Therapeutics logo
Maze Therapeutics

Biopharmaceutical

Frazier Life Sciences logo
Deep Track Capital logo
Logos Capital logo
Janus Henderson Investors logo

Maze Therapeutics is a biopharmaceutical company focused on developing precision medicines for renal and metabolic diseases using human genetics.

Series D
$115M
12/03/2024
Article

Alentis Therapeutics is a biotech company developing antibody-drug conjugates for treating Claudin-1 positive tumors and organ fibrosis.

Series D
$181.4M
11/12/2024
Article
Alpha-9 Oncology logo
Alpha-9 Oncology

Radiopharmaceuticals

Ascenta Capital logo
Lightspeed Venture Partners logo
Samsara BioCapital logo
RA Capital Management logo
Nextech Invest logo
Longitude Capital logo
General Catalyst logo
Digitalis Ventures logo

Alpha-9 Oncology Inc. develops targeted radiopharmaceuticals to improve cancer treatment.

Series C
$175M
10/23/2024
Article
Sudo Biosciences logo
Sudo Biosciences

Biopharmaceuticals

Enavate Sciences logo
TPG logo
Sanofi Ventures logo
Surveyor Capital logo
Monograph Capital logo
Frazier Life Sciences logo
Velosity Capital logo
Eventide Asset Management logo

Sudo Biosciences is a biopharmaceutical company developing TYK2 inhibitor candidates for the treatment of multiple sclerosis, neurodegenerative, and immune-mediated dermatologic diseases.

Series B
$116M
12/20/2023
Article
Lassen Therapeutics logo
Lassen Therapeutics

Clinical-stage biotech

Longitude Capital logo
Longwood Capital logo
Frazier Life Sciences logo
Catalio Capital Management logo
BVF Partners logo
Alta Partners logo

Lassen Therapeutics is a clinical-stage biotech company developing novel treatments for fibro-inflammatory diseases and cancer, focusing on therapies targeting the IL-11 and IL-18 pathways.

Series B
$85M
12/19/2023
Article